Autolus Therapeutics plc
AUTLNASDAQHealthcare● Active
$1.44
$-0.09(-6.19%)
Market Cap$381995431
P/E Ratio—
52W High$2.7
52W Low$1.175
Autolus Therapeutics plc (AUTL) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
AUTL · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
-$0.27
Est. -$0.29 · +6.9%
Revenue
$0.03B
Est. $0.03B · -0.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
AUTL reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.27 | — | — | — | $0.03B | — |
| ▲ Q2 FY2026 | May 14, 2026 | -$0.29 | -$0.27 | +6.9% | $0.03B | $0.03B | -0.2% |
| ▼ Q1 FY2026 | Mar 27, 2026 | -$0.26 | -$0.34 | -30.8% | $0.02B | $0.02B | +1.6% |
| ▼ Q4 FY2025 | Nov 12, 2025 | -$0.23 | -$0.30 | -30.4% | $0.02B | $0.02B | -13.2% |
| ▲ Q3 FY2025 | Aug 12, 2025 | -$0.24 | -$0.18 | +25.0% | $0.02B | $0.02B | -0.7% |
| ▼ Q2 FY2025 | May 8, 2025 | -$0.24 | -$0.26 | -8.3% | $0.01B | $0.00B | +309.1% |
| ▲ Q1 FY2025 | Mar 20, 2025 | -$0.21 | -$0.09 | +57.1% | $0.00B | $0.00B | -98.1% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -$0.21 | -$0.31 | -47.6% | — | $0.00B | — |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.27
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026Beat
EPS Actual
-$0.27
EPS Est.
-$0.29
EPS Surpr.
+6.9%
Revenue
$0.03B
Q1 FY2026
Mar 27, 2026Miss
EPS Actual
-$0.34
EPS Est.
-$0.26
EPS Surpr.
-30.8%
Revenue
$0.02B
Q4 FY2025
Nov 12, 2025Miss
EPS Actual
-$0.30
EPS Est.
-$0.23
EPS Surpr.
-30.4%
Revenue
$0.02B
Q3 FY2025
Aug 12, 2025Beat
EPS Actual
-$0.18
EPS Est.
-$0.24
EPS Surpr.
+25.0%
Revenue
$0.02B
Q2 FY2025
May 8, 2025Miss
EPS Actual
-$0.26
EPS Est.
-$0.24
EPS Surpr.
-8.3%
Revenue
$0.01B
Q1 FY2025
Mar 20, 2025Beat
EPS Actual
-$0.09
EPS Est.
-$0.21
EPS Surpr.
+57.1%
Revenue
$0.00B
Q4 FY2024
Nov 12, 2024Miss
EPS Actual
-$0.31
EPS Est.
-$0.21
EPS Surpr.
-47.6%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.15 | $-0.14 | $-0.13 | 2 |
| Q3 FY2028 | $-0.16 | $-0.15 | $-0.14 | 2 |
| Q2 FY2028 | $-0.17 | $-0.16 | $-0.15 | 2 |
| Q1 FY2028 | $-0.18 | $-0.17 | $-0.16 | 2 |
| Q4 FY2027 | $-0.17 | $-0.15 | $-0.14 | 1 |
| Q3 FY2027 | $-0.18 | $-0.16 | $-0.15 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q2 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q1 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q4 FY2027 | $0.0B | $0.0B | $0.1B | 2 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 14, 2026 | +6.9% | $1.71 | $1.59 | -7.02% |
| ▼ Q1 FY2026 | Mar 27, 2026 | -30.8% | $1.29 | $1.21 | -6.20% |
| ▼ Q4 FY2025 | Nov 12, 2025 | -30.4% | $1.50 | $1.36 | -9.33% |
| ▲ Q3 FY2025 | Aug 12, 2025 | +25.0% | $2.47 | $2.15 | -12.96% |
| ▼ Q2 FY2025 | May 8, 2025 | -8.3% | $1.23 | $1.35 | +9.76% |
| ▲ Q1 FY2025 | Mar 20, 2025 | +57.1% | $1.94 | $1.68 | -13.40% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -47.6% | $3.51 | $3.33 | -5.13% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -15.8% | $4.02 | $3.64 | -9.45% |
Q2 FY2026-7.02%
Report Date
May 14, 2026
EPS Beat/Miss
+6.9%
Price Before
$1.71
Price After
$1.59
Q1 FY2026-6.20%
Report Date
Mar 27, 2026
EPS Beat/Miss
-30.8%
Price Before
$1.29
Price After
$1.21
Q4 FY2025-9.33%
Report Date
Nov 12, 2025
EPS Beat/Miss
-30.4%
Price Before
$1.50
Price After
$1.36
Q3 FY2025-12.96%
Report Date
Aug 12, 2025
EPS Beat/Miss
+25.0%
Price Before
$2.47
Price After
$2.15
Q2 FY2025+9.76%
Report Date
May 8, 2025
EPS Beat/Miss
-8.3%
Price Before
$1.23
Price After
$1.35
Q1 FY2025-13.40%
Report Date
Mar 20, 2025
EPS Beat/Miss
+57.1%
Price Before
$1.94
Price After
$1.68
Q4 FY2024-5.13%
Report Date
Nov 12, 2024
EPS Beat/Miss
-47.6%
Price Before
$3.51
Price After
$3.33
Q3 FY2024-9.45%
Report Date
Aug 8, 2024
EPS Beat/Miss
-15.8%
Price Before
$4.02
Price After
$3.64
Avg Beat Reaction-11.13%
Avg Miss Reaction-4.07%
Beat Rate3 / 8 quarters
Largest Move-13.40% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: AUTL ends December
Autolus Therapeutics plc (AUTL) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $-0.27 — beating the analyst consensus of $-0.29 by +6.9%. The next AUTL earnings date is expected around September 1, 2026.
Each quarter, investors track AUTL earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. AUTL revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
AUTL's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
AUTL earnings · 5 questionsAutolus Therapeutics plc's next earnings report is expected around September 1, 2026. AUTL typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; AUTL historically reports after market close (AMC).
AUTL earnings datewhen is AUTL earningsAUTL next earnings datewhen does AUTL report earningsAUTL earnings calendar
▸ Source: FMP · Autolus Therapeutics plc SEC filings · US GAAP · Autolus Therapeutics plc SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026